X4 Pharmaceuticals Inc (XFOR) Hedge Fund Ownership (Q2 2026)

Q: Is it too late to buy X4 Pharmaceuticals Inc (XFOR) following the 2026 Q3 hedge fund 13F filings?

As of today, XFOR has moved +0.0% since the 2026 Q3 13F filing date (November 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (September 30, 2026), XFOR gained +6.9% vs +11.8% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

X4 Pharmaceuticals Inc (XFOR)

84 + Investors. Track Smart Money conviction in XFOR. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — XFOR

Based on 86 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q

For 3 consecutive quarters, more hedge funds added XFOR than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

86 hedge funds hold XFOR right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +72% more funds vs a year ago

fund count last 6Q

+36 new funds entered over the past year (+72% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟡

Slight buying edge — 58% buying

56 buying41 selling

Last quarter: 56 funds bought or added vs 41 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

📈

More new buyers each quarter (+17 vs last Q)

new funds entering per quarter

Funds opening a new XFOR position: 11 → 39 → 18 → 35. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.

🔄

Mostly new holders — 63% entered in last year

■ 1% conviction (2yr+) ■ 36% medium ■ 63% new

Only 1 funds (1%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

➡️

Steady discovery — ~35 new funds/quarter

49 → 11 → 39 → 18 → 35 new funds/Q

New funds entering each quarter: 11 → 39 → 18 → 35. Consistent flow of new institutional buyers without clear acceleration or slowdown.

🌱

Early stage — 97% of holders entered in last year

■ 2% veterans ■ 1% 1-2yr ■ 97% new

Of 87 current holders: 84 (97%) entered in the past year, only 2 (2%) are 2+ year veterans. This is an early-phase institutional idea — still being discovered. High upside potential if the thesis plays out, but thin conviction base.

✅

Strong quality — 32% AUM from major funds

32% from top-100 AUM funds

31 of 85 holders rank in the top 100 by AUM, accounting for 32% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

5.6

out of 10

Moderate Exit Risk

Exit risk score 5.6/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q2)	Prior (2026 Q1)	Change
Funds Holding	84	79	6.33%
13F Shares	94M	90M	3.62%
Total Value	$437M	$374M	16.92%
New Positions	34	18	+16
Increased Positions	21	21	-
Closed Positions	28	13	+15
Reduced Positions	13	21	-8
Total Calls	2	0	100%
Total Puts	0	0	-
PUT/CALL Ratio	0.0	0.0	Bullish

Metric

All 13F Filers (2026 Q2)

Prior (2026 Q1)

Change

Funds Holding

6.33%

13F Shares

94M

90M

3.62%

Total Value

$437M

$374M

16.92%

New Positions

+16

Increased Positions

Closed Positions

+15

Reduced Positions

-8

Total Calls

100%

Total Puts

PUT/CALL Ratio

0.0

Bullish

Institutional Holders (2026 Q3)

84 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in XFOR. Verified SEC 13F-HR filings.

QUARTER:

2026 Q3 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 XFOR holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Kalehua Capital Management LLC	8.15%	3,722,840	$10.8M
2	Palumbo Wealth Management LLC	0.03%	48,373	$140K
3	Pettinga Financial Advisors LLC	0.00%	10,000	$29K
4	Alps Advisors Inc	0.00%	130,424	$378K
5	WINTON GROUP Ltd	0.00%	10,200	$30K
6	Fmr LLC	0.00%	5,490,787	$15.9M
7	Ameritas Investment Partners, Inc.	0.00%	7,338	$21K
8	Russell Investments Group, Ltd.	0.00%	213,258	$618K
9	Police & Firemen's Retirement System of New Jersey	0.00%	23,846	$69K
10	Renaissance Technologies LLC	0.00%	115,524	$335K
11	Vanguard Fiduciary Trust Co	0.00%	512,811	$1.5M
12	Squarepoint Ops LLC	0.00%	83,488	$242K
13	Vanguard Capital Management LLC	0.00%	3,558,591	$10.3M
14	Rhumbline Advisers	0.00%	94,984	$275K
15	Bleichroeder LP	0.00%	595	$2K
16	American Century Companies Inc	0.00%	113,736	$330K
17	Sterling Capital Management LLC	0.00%	1,652	$5K
18	Vanguard Portfolio Management LLC	0.00%	572,106	$1.7M
19	Deutsche Bank Ag\	0.00%	68,976	$200K
20	Stifel Financial Corp	0.00%	20,291	$59K
21	Voya Investment Management LLC	0.00%	16,665	$48K
22	ProShare Advisors LLC	0.00%	10,533	$31K
23	Citigroup Inc	0.00%	42,762	$124K
24	GAMMA Investing LLC	0.00%	385	$1K
25	Barclays plc	0.00%	39,770	$115K

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — X4 Pharmaceuticals Inc (XFOR)

What does the Smart Money Trend signal show for XFOR?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added XFOR than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for XFOR?

Slight buying edge — 58% buying: Last quarter: 56 funds bought or added vs 41 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for XFOR holders?

Strong quality — 32% AUM from major funds: 31 of 85 holders rank in the top 100 by AUM, accounting for 32% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held XFOR?

Mostly new holders — 63% entered in last year: Only 1 funds (1%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy X4 Pharmaceuticals Inc (XFOR) following the 2026 Q3 hedge fund 13F filings?

As of today, XFOR has moved +0.0% since the 2026 Q3 13F filing date (November 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (September 30, 2026), XFOR has gained +6.9% vs +11.8% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

X4 Pharmaceuticals Inc (XFOR)

Smart Money Signals — XFOR

Buying streak — 3 quarters in a row

At the ownership peak (100% of max)

Fast accumulation — +72% more funds vs a year ago

Slight buying edge — 58% buying

More new buyers each quarter (+17 vs last Q)

Mostly new holders — 63% entered in last year

Steady discovery — ~35 new funds/quarter

Early stage — 97% of holders entered in last year

Strong quality — 32% AUM from major funds

Institutional Sentiment Summary — XFOR

Hedge Fund Ownership: XFOR

Market Analysis: XFOR

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: XFOR

Is It Too Late to Buy X4 Pharmaceuticals Inc (XFOR) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: XFOR

Statistics: XFOR

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q3)

Frequently Asked Questions — X4 Pharmaceuticals Inc (XFOR)

Welcome to 13Foresight!